-+ 0.00%
-+ 0.00%
-+ 0.00%

Cytokinetics Wins Health Canada Approval for MYQORZO to Treat Obstructive HCM

PUBT·10/19/2026 11:36:40
Listen to the news
Cytokinetics Wins Health Canada Approval for MYQORZO to Treat Obstructive HCM
  • Health Canada approved Cytokinetics' MYQORZO (aficamten) for adults with symptomatic obstructive hypertrophic cardiomyopathy classified as NYHA class II-III.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cytokinetics Incorporated published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610190730PRIMZONEFULLFEED9848098) on October 19, 2026, and is solely responsible for the information contained therein.